| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BB BIOTECH AG | 4.8% | -68.7% | $4.37M | -$9.25M | 2.73M | -67.9% | BB Biotech AG | 19 Mar 2025 |
| BlackRock, Inc. | 4.5% | $4.04M | 2.52M | BlackRock, Inc. | 31 Mar 2025 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Change | Price | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 38.8M | $147M | +$5.64M | $3.79 | 89 |
| 2025 Q2 | 38.6M | $95.8M | -$4.38M | $2.48 | 92 |
| 2025 Q1 | 40.7M | $63M | -$11.8M | $1.55 | 83 |
| 2024 Q4 | 47.9M | $103M | -$13.8M | $2.14 | 85 |
| 2024 Q3 | 48.7M | $212M | +$1.57M | $4.35 | 95 |
| 2024 Q2 | 46.8M | $218M | +$31.7M | $4.66 | 88 |
| 2024 Q1 | 39.4M | $200M | +$10.7M | $5.07 | 86 |
| 2023 Q4 | 38.1M | $107M | +$4.41M | $2.81 | 73 |
| 2023 Q3 | 37.2M | $107M | -$21.9M | $2.87 | 71 |
| 2023 Q2 | 41.4M | $209M | +$105M | $5.05 | 72 |
| 2023 Q1 | 21.5M | $40.6M | +$847K | $1.89 | 47 |
| 2022 Q4 | 21.1M | $37.9M | -$722K | $1.80 | 56 |
| 2022 Q3 | 21.5M | $36.3M | -$285K | $1.69 | 57 |
| 2022 Q2 | 21.5M | $52.9M | -$3.55M | $2.46 | 56 |
| 2022 Q1 | 22.9M | $64.1M | -$2.43M | $2.77 | 69 |
| 2021 Q4 | 23.2M | $124M | -$13M | $5.33 | 83 |
| 2021 Q3 | 24.4M | $206M | -$11.2M | $8.46 | 89 |
| 2021 Q2 | 25.4M | $310M | -$81.4M | $12.19 | 97 |
| 2021 Q1 | 29.1M | $706M | -$7.56M | $24.26 | 109 |
| 2020 Q4 | 28.6M | $917M | +$140M | $32.05 | 109 |
| 2020 Q3 | 23.8M | $718M | +$754K | $30.23 | 88 |
| 2020 Q2 | 22.8M | $959M | +$39.9M | $42.16 | 79 |
| 2020 Q1 | 22.3M | $555M | +$555M | $24.95 | 65 |